Literature DB >> 29528390

Expression of C9orf72-related dipeptides impairs motor function in a vertebrate model.

Amrutha Swaminathan1, Marilou Bouffard1, Meijiang Liao1, Sarah Ryan2, Janis Bennion Callister2, Stuart M Pickering-Brown2, Gary Alan Barclay Armstrong3, Pierre Drapeau1.   

Abstract

Large expansions of hexanucleotide GGGGCC (G4C2) repeats (hundreds to thousands) in the first intron of the chromosome 9 open reading frame 72 (C9orf72) locus are the strongest known genetic factor associated with amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Different hypotheses exist about the underlying disease mechanism including loss of function by haploinsufficiency, toxicity arising as a result of RNA or dipeptide repeats (DPRs). Five different DPRs are produced by repeat-associated non-ATG-initiated translation of the G4C2 repeats. Though earlier studies have indicated toxicity of the DPRs in worms, flies, primary cultured cells and cell lines, the effect of expressing DPRs of amyotrophic lateral sclerosis-relevant length has not been tested on motor behaviour in vertebrate models. In this study, by expressing constructs with alternate codons encoding different lengths of each DPR (40, 200 and 1000) in the vertebrate zebrafish model, the GR DPR was found to lead to the greatest developmental lethality and morphological defects, and GA, the least. However, expressing 1000 repeats of any DPR, including the 'non-toxic' GA DPR led to locomotor defects. Based on these observations, a transgenic line stably expressing 100 GR repeats was generated to allow specific regional and temporal expression of GR repeats in vivo. Expression of GR DPRs ubiquitously resulted in severe morphological defects and reduced swimming. However, when expressed specifically in motor neurons, the developmental defects were significantly reduced, but the swimming phenotype persisted, suggesting that GR DPRs have a toxic effect on motor neuron function. This was validated by the reduction in motor neuron length even in already formed motor neurons when GR was expressed in these. Hence, the expression of C9orf72-associated DPRs can cause significant motor deficits in vertebrates.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29528390      PMCID: PMC5932562          DOI: 10.1093/hmg/ddy083

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  21 in total

1.  Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.

Authors:  Mariely DeJesus-Hernandez; Ian R Mackenzie; Bradley F Boeve; Adam L Boxer; Matt Baker; Nicola J Rutherford; Alexandra M Nicholson; NiCole A Finch; Heather Flynn; Jennifer Adamson; Naomi Kouri; Aleksandra Wojtas; Pheth Sengdy; Ging-Yuek R Hsiung; Anna Karydas; William W Seeley; Keith A Josephs; Giovanni Coppola; Daniel H Geschwind; Zbigniew K Wszolek; Howard Feldman; David S Knopman; Ronald C Petersen; Bruce L Miller; Dennis W Dickson; Kevin B Boylan; Neill R Graff-Radford; Rosa Rademakers
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

2.  Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration.

Authors:  Clotilde Lagier-Tourenne; Michael Baughn; Frank Rigo; Shuying Sun; Patrick Liu; Hai-Ri Li; Jie Jiang; Andrew T Watt; Seung Chun; Melanie Katz; Jinsong Qiu; Ying Sun; Shuo-Chien Ling; Qiang Zhu; Magdalini Polymenidou; Kevin Drenner; Jonathan W Artates; Melissa McAlonis-Downes; Sebastian Markmiller; Kasey R Hutt; Donald P Pizzo; Janet Cady; Matthew B Harms; Robert H Baloh; Scott R Vandenberg; Gene W Yeo; Xiang-Dong Fu; C Frank Bennett; Don W Cleveland; John Ravits
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-29       Impact factor: 11.205

Review 3.  Distinct neurological disorders with C9orf72 mutations: genetics, pathogenesis, and therapy.

Authors:  Song Chi; Teng Jiang; Lan Tan; Jin-Tai Yu
Journal:  Neurosci Biobehav Rev       Date:  2016-04-30       Impact factor: 8.989

Review 4.  The delivery of therapeutic oligonucleotides.

Authors:  Rudolph L Juliano
Journal:  Nucleic Acids Res       Date:  2016-04-15       Impact factor: 16.971

5.  Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells.

Authors:  Ilmin Kwon; Siheng Xiang; Masato Kato; Leeju Wu; Pano Theodoropoulos; Tao Wang; Jiwoong Kim; Jonghyun Yun; Yang Xie; Steven L McKnight
Journal:  Science       Date:  2014-07-31       Impact factor: 47.728

6.  RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention.

Authors:  Christopher J Donnelly; Ping-Wu Zhang; Jacqueline T Pham; Aaron R Haeusler; Aaron R Heusler; Nipun A Mistry; Svetlana Vidensky; Elizabeth L Daley; Erin M Poth; Benjamin Hoover; Daniel M Fines; Nicholas Maragakis; Pentti J Tienari; Leonard Petrucelli; Bryan J Traynor; Jiou Wang; Frank Rigo; C Frank Bennett; Seth Blackshaw; Rita Sattler; Jeffrey D Rothstein
Journal:  Neuron       Date:  2013-10-16       Impact factor: 17.173

7.  Glycine-alanine dipeptide repeat protein contributes to toxicity in a zebrafish model of C9orf72 associated neurodegeneration.

Authors:  Yu Ohki; Andrea Wenninger-Weinzierl; Alexander Hruscha; Kazuhide Asakawa; Koichi Kawakami; Christian Haass; Dieter Edbauer; Bettina Schmid
Journal:  Mol Neurodegener       Date:  2017-01-14       Impact factor: 14.195

8.  Modelling C9orf72 dipeptide repeat proteins of a physiologically relevant size.

Authors:  Janis Bennion Callister; Sarah Ryan; Joan Sim; Sara Rollinson; Stuart M Pickering-Brown
Journal:  Hum Mol Genet       Date:  2016-12-01       Impact factor: 6.150

9.  C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins.

Authors:  Sarah Mizielinska; Sebastian Grönke; Teresa Niccoli; Charlotte E Ridler; Emma L Clayton; Anny Devoy; Thomas Moens; Frances E Norona; Ione O C Woollacott; Julian Pietrzyk; Karen Cleverley; Andrew J Nicoll; Stuart Pickering-Brown; Jacqueline Dols; Melissa Cabecinha; Oliver Hendrich; Pietro Fratta; Elizabeth M C Fisher; Linda Partridge; Adrian M Isaacs
Journal:  Science       Date:  2014-08-07       Impact factor: 47.728

10.  C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice.

Authors:  Amanda Atanasio; Vilma Decman; Derek White; Meg Ramos; Burcin Ikiz; Hoi-Ching Lee; Chia-Jen Siao; Susannah Brydges; Elizabeth LaRosa; Yu Bai; Wen Fury; Patricia Burfeind; Ralica Zamfirova; Gregg Warshaw; Jamie Orengo; Adelekan Oyejide; Michael Fralish; Wojtek Auerbach; William Poueymirou; Jan Freudenberg; Guochun Gong; Brian Zambrowicz; David Valenzuela; George Yancopoulos; Andrew Murphy; Gavin Thurston; Ka-Man Venus Lai
Journal:  Sci Rep       Date:  2016-03-16       Impact factor: 4.379

View more
  20 in total

1.  The Novel Small Molecule TRVA242 Stabilizes Neuromuscular Junction Defects in Multiple Animal Models of Amyotrophic Lateral Sclerosis.

Authors:  Poulomee Bose; Elsa Tremblay; Claudia Maois; Vijay Narasimhan; Gary A B Armstrong; Meijiang Liao; J Alex Parker; Richard Robitaille; Xiao Yan Wen; Christopher Barden; Pierre Drapeau
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

Review 2.  Repeat-associated non-AUG (RAN) translation: insights from pathology.

Authors:  Monica Banez-Coronel; Laura P W Ranum
Journal:  Lab Invest       Date:  2019-03-27       Impact factor: 5.662

3.  Knock in of a hexanucleotide repeat expansion in the C9orf72 gene induces ALS in rats.

Authors:  Wei Dong; Li Zhang; Caixian Sun; Xiang Gao; Feifei Guan; Jing Li; Wei Chen; Yuanwu Ma; Lianfeng Zhang
Journal:  Animal Model Exp Med       Date:  2020-08-07

Review 4.  The clinical trial landscape in amyotrophic lateral sclerosis-Past, present, and future.

Authors:  Heike J Wobst; Korrie L Mack; Dean G Brown; Nicholas J Brandon; James Shorter
Journal:  Med Res Rev       Date:  2020-02-11       Impact factor: 12.944

Review 5.  C9orf72-mediated ALS and FTD: multiple pathways to disease.

Authors:  Rubika Balendra; Adrian M Isaacs
Journal:  Nat Rev Neurol       Date:  2018-09       Impact factor: 42.937

6.  Widespread displacement of DNA- and RNA-binding factors underlies toxicity of arginine-rich cell-penetrating peptides.

Authors:  Vanesa Lafarga; Oleksandra Sirozh; Irene Díaz-López; Antonio Galarreta; Misaru Hisaoka; Eduardo Zarzuela; Jasminka Boskovic; Bogdan Jovanovic; Rafael Fernandez-Leiro; Jaime Muñoz; Georg Stoecklin; Iván Ventoso; Oscar Fernandez-Capetillo
Journal:  EMBO J       Date:  2021-05-12       Impact factor: 14.012

Review 7.  Animal models of amyotrophic lateral sclerosis: A comparison of model validity.

Authors:  Jessica R Morrice; Cheryl Y Gregory-Evans; Christopher A Shaw
Journal:  Neural Regen Res       Date:  2018-12       Impact factor: 5.135

Review 8.  Existing and Emerging Metabolomic Tools for ALS Research.

Authors:  Christine Germeys; Tijs Vandoorne; Valérie Bercier; Ludo Van Den Bosch
Journal:  Genes (Basel)       Date:  2019-12-05       Impact factor: 4.096

9.  Reduced C9orf72 function leads to defective synaptic vesicle release and neuromuscular dysfunction in zebrafish.

Authors:  Zoé Butti; Yingzhou Edward Pan; Jean Giacomotto; Shunmoogum A Patten
Journal:  Commun Biol       Date:  2021-06-25

Review 10.  Divergence, Convergence, and Therapeutic Implications: A Cell Biology Perspective of C9ORF72-ALS/FTD.

Authors:  Xiaoqiang Tang; Arturo Toro; Sahana T G; Junli Gao; Jessica Chalk; Björn Oskarsson; Ke Zhang
Journal:  Mol Neurodegener       Date:  2020-06-08       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.